Five things we learned about FDA nominee Scott Gottlieb
In his confirmation hearing, Trump's nominee for FDA Commissioner Scott Gottlieb responded to his alleged conflicts of interest, questions about the opioid epidemic and more.
FDA: More basic science research needed to accelerate cures
Robert Califf, a deputy commissioner at the FDA, says that in order to accelerate medical treatment options for diseases like Alzheimer's, we must improve our basic understanding of disease processes.
With the Rise of AI, What IP Disputes in Healthcare Are Likely to Emerge?
Munck Wilson Mandala Partner Greg Howison shared his perspective on some of the legal ramifications around AI, IP, connected devices and the data they generate, in response to emailed questions.
Drug approvals hit an 18-year high in 2014
With 41 novel drug approvals under the regulators’ belts last year, 2014 represented an 18-year high for the Food and Drug Administration – including a record number of okayed meds for orphan diseases, the Associated Press says: FDA drug approvals are considered a barometer of industry innovation and the federal government’s efficiency in reviewing new […]